Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (th

Original reporting
Published Sep 28, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GCTK
Bullish
high confidence
Mentioned
$GCTK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GCTKBullishMed
01

Why it matters

The removal of floor‑price adjustments may improve shareholder equity but could affect investor appetite for future debt.

02

Market read

Primary disclosure of financing amendment; likely short‑term price impact for GCTK.

03

What to watch

Potential impact on future fundraising ability and covenant compliance.

Relevance 6/10Novelty 7/10Timing: immediate filing impact

Background

Glucotrack, Inc. (GCTK) filed a Form 8‑K reporting entry into a material definitive agreement involving bridge and September note/warrant amendments.

Company-level read

Ticker impact

$GCTKBullishHigh confidence
Context

SEC 8‑K filing discloses multiple amendments to bridge and September warrant agreements, removing floor‑price adjustments and altering conversion terms.

Expected impact

likely upward pressure as market prices in reduced dilution and clearer capital structure

Evidence & confidence

Amendments remove protective provisions for investors that could have lowered conversion prices, improving equity value for existing shareholders.

Market effects

May set a precedent for other micro‑cap biotech financing structures.

Limited to U.S. OTC market participants.

Low

Counterpoint

Amendments could signal tighter financing conditions, hinting at future cash constraints.

Key entities

  • Glucotrack, Inc.

    Micro‑cap biotech issuing convertible notes and warrants.

  • Bridge Investors

    Initial holders of bridge notes and warrants.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.